Approval · Notice of Compliance 36852 · 2026
RETEVMO: Notice of Compliance 36852
Issued February 6, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36852
- Date
- February 6, 2026
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph reformatted to the Master Template. Addition of new dosage form: Tablet.
Products in this notice
Medicinal ingredients
- SELPERCATINIB 40 MG per TAB
- SELPERCATINIB 80 MG per TAB